Drug
Ak109 Ak104
Ak109 Ak104: highest development phase Phase 1/2, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK109+AK104 NCT05142423 | Phase 1/2 | Advanced Solid Tumor |
Latest
No recent events.
Follow Ak109 Ak104 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.